No. 24-889, October Term 2025. Decided, 9–0, opinion by Justice Jackson.
Amarin makes the brand-name drug Vascepa, which is approved for two uses, and holds patents on one of them, reducing cardiovascular risk. Hikma won approval to sell a generic version with a "skinny label" that leaves out the patented use. Amarin sued under the patent law's ban on actively inducing others to infringe, and the Court took up whether Hikma's statements plausibly alleged that.
The Court held that Amarin failed to state a claim for actively inducing infringement, so its complaint must be dismissed. Justice Jackson, writing for a unanimous Court, said Amarin had to plausibly allege that Hikma took active steps to encourage infringing use. Hikma's statements were legally required, standard industry practice, omissions, or too vague. The Court reversed the Federal Circuit and sent the case back, 9 to 0.
Amarin has failed to state a claim for active inducement in violation of § 271(b), so its complaint cannot withstand Hikma's motion to dismiss. The central question is whether Amarin plausibly alleged that Hikma actively encouraged infringing use, not merely whether doctors could plausibly read the alleged statements as instructions to infringe.